(Q22252970)

English

5-alpha-reductase inhibitors for prostate cancer prevention

scientific article

Five-alpha-reductase Inhibitors for prostate cancer prevention

In more languages

edit

Statements

0 references

0 references

1 reference

Europe PubMed Central

title

5-alpha-reductase inhibitors for prostate cancer prevention (English)

0 references

1 reference

1

Timothy J Wilt

T J

Wilt

1 reference

7 February 2023

5

B S

Kramer

Barnett S Kramer

1 reference

7 February 2023

Roderick MacDonald

2

R

MacDonald

1 reference

7 February 2023

Karen Hagerty

series ordinal

3

author given names

K

author last names

Hagerty

1 reference

7 February 2023

Paul Schellhammer

series ordinal

4

author given names

P

author last names

Schellhammer

1 reference

7 February 2023

language of work or name

English

0 references

publication date

23 April 2008

0 references

published in

Cochrane Database of Systematic Reviews

0 references

page(s)

CD007091

0 references

issue

2

0 references

cites work

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

The influence of finasteride on the development of prostate cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Prostate cancer prevention and finasteride

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Meta-analysis in clinical trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Measuring inconsistency in meta-analyses

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

21 January 2018

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Finasteride on the Sensitivity of PSA for Detecting Prostate Cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007091

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD007091

0 references

Fatcat ID

release_k4ywe7sr4jfwnktvjbxch7dkvu

0 references

PubMed ID

18425978

0 references

(Q22252970)

5-alpha-reductase inhibitors for prostate cancer prevention

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)